Back to search

Article

A needle-free subunit vaccine platform inducing mucosal and systemic antibody immunity

2022-07-21

Abstract excerpt

<title>Abstract</title> <p>While the established route for vaccines against the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is intramuscular, it may be preferable to deliver vaccines intranasally to secure mucosal protection at the site of infection. This will limit the spread of the virus, ease administration and likely improve vaccine acceptance. Here, we report on a subunit vaccine pl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e7b1728b-2ea1-5f4d-8528-f6102b8a6294
DOI
10.21203/rs.3.rs-1727649/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A needle-free subunit vaccine platform inducing mucosal and systemic antibody immunityDOI 10.21203/rs.3.rs-1727649/v1
Inhalable SARS-CoV-2 vaccine for single-dose dry powder aerosol immunizationSemantic proximity
Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccineSemantic proximity
An intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infectionSemantic proximity
Efficacy of a stable multivalent broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity
Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform.Semantic proximity
A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 InfectionSemantic proximity
Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platformSemantic proximity
Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunitySemantic proximity
A multicomponent intranasal adjuvant drives durable humoral, cellular, and mucosal immune responses to SARS-CoV-2 in young and aged mice.Semantic proximity
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in miceSemantic proximity
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in miceSemantic proximity
Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine designSemantic proximity
Select a neighboring publication to make it the new centre.